Selective Targeting of Different Bromodomains by Small Molecules
- PMID: 32516588
- DOI: 10.1016/j.ccell.2020.05.016
Selective Targeting of Different Bromodomains by Small Molecules
Abstract
Two papers, published in Science and Nature, report inhibitiors selectively targeting distinct bromodomains of BET proteins. These advanced chemical tools facilitate functional understanding of epigenetic regulators in normal and disease states and enable development of new medicine potentially with lower toxicity.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Interests J.Q. is a scientific co-founder and consultant for Epiphanes and is a shareholder of Zentalis. Y.S. is a scientific co-founder and equity holder of Constellation Pharmaceuticals and Athelas Therapeutics, an equity holder of Imago Biosciences, and a consultant for Active Motif.
Comment on
-
Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.Nature. 2020 Feb;578(7794):306-310. doi: 10.1038/s41586-020-1930-8. Epub 2020 Jan 22. Nature. 2020. PMID: 31969702
-
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation.Science. 2020 Apr 24;368(6489):387-394. doi: 10.1126/science.aaz8455. Epub 2020 Mar 19. Science. 2020. PMID: 32193360 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical